THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
发明人:
GACZYNSKA, MARIA, E.,OSMULSKI, PAWEL, A.
申请号：
EP13869967
公开号：
EP2941301A4
申请日:
2013.12.24
申请国别(地区):
EP
年份:
2016
代理人:
摘要：
The invention provides for treatment of cancers using a rapamycin analog, optionally including bortezomib. In particular, the invention addresses the treatment of bortezomib-resistant cancers using seco-rapamycin and optionally a second proteasome inhibitor. This invention relates to oncology and medicine, and more particularly to treatment of cancer. In particular, rapamycin analogs such as seco-rapamycin may be used advantageously to target the proteasome in cancer cells, optionally in conjunction with proteasome inhibitors such as bortezomib.
